همایش ملی بیوانفورماتیک ایران

صفحه اصلی / 4th international edition and 13th Iranian Conference on Bioinformatics

Innovative Multi-Epitope Vaccine for Breast Cancer Management: Utilizing MAGE-A, MAM-A, and Gal-3 through an In Silico Reverse Vaccinology Approach

نویسندگان :

Faranak Aali¹ Abbas Doosti² Mostafa Shakhsi-Niaei³

1- Department of Biology, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran 2- Biotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran 3- Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran

کلمات کلیدی :

Breast cancer،Immunotherapy،Reverse vaccinology،Multiepitope vaccine

چکیده :

Breast cancer (BC) is one of the most common cancers among women, and its prevalence is alarmingly on the rise. There is an urgent need to develop effective therapies due to the high prevalence and increasing incidence of this disease. Currently, traditional passive treatments have significant limitations that remain unresolved. In contrast, innovative immunotherapy strategies, such as cancer vaccines, have shown promising potential in addressing advanced stages of breast cancer. The primary objective of this research was to formulate a multiepitope vaccine for breast cancer using the MAGE-A, MAM-A, and Gal-3 antigenic proteins. To elicit robust immune responses, first antigenic epitopes of these proteins identified and evaluated their immunogenicity. To minimize functional immunogenicity, we conjugated promiscuous epitopes with an appropriate adjuvant (IL-12 protein) and linked them using a suitable linker (GSST). Then, enhanced and validated an optimal three-dimensional model to obtain a superior structure was done. Molecular docking studies and dynamic modeling were employed to assess the structural stability and integrity of the vaccine in complex with mouse TLR-2, TLR-4, and TLR-7. The vaccine was then optimized and cloned into the pcDNA3.1(+) vector. Additionally, immunological simulations of the vaccine demonstrated its ability to elicit immune responses, including B cells, T cells, antibodies, and cytokines, against breast cancer. Overall, the immunoinformatic analysis of the developed vaccine indicates its potential to generate strong humoral and cellular immune responses in the targeted organism. Therefore, it shows promise as a therapeutic agent against breast cancer and further investigation in this field.